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Case Report Dihydrotachysterol intoxication treated with 
pamidronate: a case report
Mojca Jensterle, Marija Pfeifer, Matjaz Sever and Tomaz Kocjan*
Abstract
Introduction: Hypoparathyroidism is a chronic condition which requires a lifelong substitution with vitamin D 
analogues and careful monitoring. This is especially true for older patients and older compounds as dihydrotachysterol 
with longer half-life that might lead to long-lasting hypercalcemic episodes.
Case presentation: A 74-year old male patient with postsurgical hypoparathyroidism who has been successfully 
supplemented with dihydrotachysterol (1.7 ml/day) for over 50 years presented with neuropsychiatric disturbances, 
constipation, renal insufficiency and polyuria. Laboratory investigation demonstrated serum calcium 3.7 mmol/L, 
serum creatinine 180 micromol/L, urine calcium excretion 1.1 mmol/mmol of the creatinine, normal 25 OH vitamin D3 
and low parathormone and 1,25 di OH vitamin D3. Careful history revealed that he has been erroneously taking 2.5 ml 
of dihydrotachysterol per day for at least 6 to 8 weeks that caused vitamin D intoxication and symptomatic 
hypercalcemia. He was treated with intravenous saline infusion, prednisolone and 60 mg of intravenous sodium 
pamidronate. On the fourth day after admission serum calcium dropped rapidly within the reference range. The 
treatment for hypoparathyroidism had to be reinstituted 10 days after dihydrotachysterol had been discontinued when 
the patient was switched to shorter acting calcitriol.
Conclusions: Here we reported that the immediate use of pamidronate in addition to classic treatment of 
dihydrotachysterol intoxication with intravenous saline, diuretics and glucocorticoids is an effective treatment choice 
that leads to rapid resolution of hypercalcemia.
Background
Vitamin D intoxication is a rare cause of hypercalcemia.
However , it should be considered even after uneventful
chronic therapy of hypoparathyroidism, especially in
older patients. Common treatment regimens for
hypoparathyroidism include colecalciferol (vitamin D3)
or ergocalciferol (vitamin D2), alfacalcidol (1 alpha-
hydroxycolecalciferol) and calcitriol. Colecalciferol and
ergocalciferol are the least expensive preparations but
have the longest duration of action. This is due to the
storage of these compounds in body fat and consequent
slow release which may result in prolonged toxicity. The
newer preparations, alfacalcidol and calcitriol, which do
not require renal 1 alpha hydroxylation, are much more
potent, have the advantage of shorter half-life and thereby
minimal risk of prolonged toxicity. Calcitriol is the natu-
ral active metabolite and, unlike alfacalcidol, does not
require the hepatic 25-hydroxylation [1]. Nowadays, it is
the drug of choice for treating hypoparathyroidism.
Dihydrotachysterol is only seldom used in the treat-
ment of hypoparathyroidism. It is a half synthetic analog
of vitamin D and is converted to the active form in the
body. Dihydrotachysterol actions and pharmacokinetics
resemble those of vitamin D3 including the prolonged
toxicity. It stimulates calcium and phosphate absorption
from the small intestine, promotes mobilization of cal-
cium from bone to blood and promotes renal tubular
reabsorption of phosphate. It is stored in liver, fat, skin,
muscle, and bone and excreted in feces. Its peak effect on
serum calcium concentration is reached in 2-4 weeks and
lasts for about 9 weeks which means a prolonged toxicity.
It is of note, that dihydrotachysterol is not detected by the
25 OH D3 and 1,25 di OH vitamin D3 assays [2].
Vitamin D intoxication is a treatable cause of hypercal-
cemia. Calcitriol-induced hypercalcemia usually lasts
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only one to two days due to the short biologic half-life of
the compound. Discontinuing the calcitriol, increasing
salt and fluid intake or additional hydration with intrave-
nous saline may be the only treatment needed. In con-
trast, hypercalcemia induced by intoxication with longer
lasting preparations such as dihydrotachysterol, vitamin
D3 and vitamin D2 takes longer to resolve because of
deposition of ingested vitamin D in fat and its consequent
slow release. Therefore, more aggressive therapy includ-
ing intravenous hydration, diuretics and glucocorticoids
is needed.
However, it has been demonstrated that the major
cause of hypercalcemia due to vitamin D intoxication is
actually the increased bone resorption [3]. If this is the
case, specific inhibitors of bone resorption as bisphos-
phonates might provide more effective treatment than
conventional therapy. We carried out a systematic review
of most previously published case reports using bisphos-
phonate treatment in patients with vitamin D intoxica-
tion. The results are presented in Table 1[4-15]. We also
found three review articles that are reported in the fol-
lowing paragraph.
Selby et al. [3] observed a rapid reduction in plasma cal-
cium concentration with pamidronate in a group of
patients with vitamin D intoxication. In the same group
corticosteroids had a more delayed effect. They con-
cluded that hypercalcemia of vitamin D intoxication is
mediated by increased bone resorption and bisphospho-
nates should have a role in its management. Rizzoli et al.
[16] reported that intravenous administration of clo-
dronate corrected hypercalcemia and hypercalciuria of
vitamin D intoxication whereas prednisolone therapy
barely affected biochemical values. Finally, Quack et al.
[17] reported successful application of single dose
pamidronate 15 mg even in four patients with dihydrota-
cysterol intoxication regardless of their renal failure.
To our knowledge, the combination of conventional
treatment and pamidronate, has never been introduced
simultaneously and immediately after admittance in a
patient with dihydrotachysterol intoxication. Considering
the extremely brisk response in our patient we believe
that this is an effective and advantageous treatment regi-
men which also enables rapid reinstitution of the substi-
tution therapy.
Case presentation
A 74-year old male patient was sent to the emergency
neurologic outpatient clinic because of progressive con-
fusion, lethargy, dysarthria, fatigue and weakness in the
last week. He complained of constipation, anorexia and
vague abdominal pain. The CT scan of the brain that was
immediately performed by the neurologist was normal.
An interview with his son who arrived a few hours later
revealed that the patient had been treated for hyperten-
sion and postsurgical hypoparathyroidism without any
other important comorbidity. He was followed regularly
at an endocrinology outpatient clinic once yearly. His last
visit two months before current admission showed nor-
mal laboratory values including serum calcium, creati-
nine and phosphate. He had near-total thyroidectomy for
benign goiter back in 1955. Following the surgery he had
episodes of tetany and postsurgical hypoparathyroidism
was diagnosed 2 years later. A therapy with dihydrot-
achysterol was introduced in 1957. In 1972 he had a sin-
gle episode of renal colic which ended with spontaneous
stone passage. In 1995 thiazide diuretic was added to the
dihydrotachysterol due to hypercalciuria. There were sev-
eral attempts to introduce shorter acting vitamin D deriv-
atives during 50 years of the disease history, but finally
the patient had always rejected all new medications and
switched back to dihydrotachysterol.
On examination, he was lethargic, dysarthric with slow
tongue movements and poor cognitive estimates, hyper-
tensive (blood pressure was 165/95 mmHg), dehydrated.
Cardiovascular, respiratory and abdominal examinations
were unremarkable. Cranial nerve examination was nor-
mal. He had bradykinesia with decreased power of the
limbs, in association with decreased reflexes and slightly
increased tone in the axial parts of the limbs. Plantar
responses were normal. After admission we noted also
severe constipation and polyuria few days later.
When laboratory investigations demonstrated serum
calcium of 3.7 mmol/L, serum creatinine 188 μmol/L and
urea 16.2 mmol/L, he was admitted to the endocrinology
department where some additional tests were done. Uri-
nary calcium excretion in the 24 hours collection was
increased to 1.1 mmol/mmol of creatinine. Alkaline
phosphatase, phosphate, 25 OH vitamin D3, ACE (angio-
tensin converting enzyme), PSA and CEA were normal.
Serum parathormone and 1,25 di OH vitamin D3 were
low (Table 2). The QTc interval on ECG was within refer-
ence range. Test of occult blood in stool specimen was
negative. Abdominal ultrasound showed normally sized
kidneys, no renal calculi and no nephrocalcinosis. Chest
X-ray was normal.
Based on the history the patient was diagnosed with
vitamin D intoxication due to dihydrotachysterol over-
dose. Differential diagnosis included malignancy and sar-
coidosis. However, according to the data collected they
seemed unlikely and therapy was initiated before their
proper exclusion. The patient was treated according to
conventional treatment regimen for this condition with
intravenous saline infusion, careful administration of
loop diuretic (furosemide) and methylprednisolone. We
additionally applied 60 mg of pamidronate sodium in
slow intravenous infusion over 4 hours. Two days after
the admission the patient became less confused. His com-
munication improved and he admitted that he had beenJ
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Table 1: Systematic review of previously published case reports using bisphosphonate treatment in patients with vitamin D intoxication.
Ref. Age, Sex Underlying 
disease
Vitamin D 
compound
Serum Ca/P 
(mg/dl)
Creatinine 
(mg/dl)
PTH (pg/ml) 25 OH D3 
(ng/ml)
Treatment Other 
treatment
Response 
time
4. 40 years, M Hypoparathyr
oidism
Ergocalciferol 
100.000 U/day 
for 3 years
13.0 4.2 121 Disodium 
etidronate 400 
mg
Hydration, 
prednisone
42 weeks
5. 7 months None Vitamin D Alendronate
6. 3 months, M None Vitamin D 
1.200.000 U/
day
18.5/3.2 < 1.0 360 Alendronate 
5-10 mg/day
Hydration, 
diuretics
18 days
7. 31 years, F Hypoparathyr
oidism
Dyhydrotahys
terol 4 mg/day 
for 6 months
4.1 mmol 5.5 Pamidronate 
20 mg once
Hydration, 
diuretics
20 weeks
8. 16 months, M None Vitamin D 18 Pamidronate Hydration, 
furosemide, 
glucocortioids
9. 8 months, F Vitamin D 
deficiency
25-hydroxy 
vitamin D 
1.200.000 U
14.2/4.8 < 3 210 Alendronate 5 
mg/day
Hydration, 
furosemide
3 days
9. 35 days, M Vitamin D 
deficiency
25-hydroxy 
vitamin D 
600.000 U
14.5/5.9 < 3 240 Alendronate 
5-10 mg/day
Hydration, 
furosemide
8 days
10. 3 months, M None Vitamin D 
2.560.000 U
16.4/6.7 268 Pamidronate 
20 mg twice
Hydration, 
furosemide, 
prednisolone
36 hoursJ
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11. 6 months None Vitamin D Pamidronate 1 
mg/kg/day 
twice
Hydration, 
furosemide, 
calcitonine, 
prednisolone
2 days
12. 11 months, F None Cholecalcifero
l > 900.000 U
18 1.84 200 Alendronat 5 
mg/day for 21 
days
Calcitonine, 
glucocorticoid
, oral 
phosphates
3 weeks
12. 4 months, F Misdiagnosed 
for rickets
Cholecalcifero
l 600.000 U
14.9 4.1 > 160 Pamidronate, 
1 mg/kg/day 
for 9 days, 
alendronate 
10 mg/day for 
6 weeks
Hydration, 
glucocrticoids, 
calcitonin, 
phosphates
9 weeks
13. 77 years, F Osteoporosis Vitamin D 
50.000 U/day 
for 6 days
21 1.9 280 Pamidronate 
90 mg once
Hydration 24 hours
14. 7 years, M Vitamin D 
deficiency
Vitamin D 
300.000 U/day 
for 15 days
12.1/3.4 > 400 Alendronate 
5-10 mg
Hydration, 
diuretic
16 days
15. 76 years, F Hypoparathyr
oidism
Ergocalciferol 
100.000 U/
day, 12 years
15.3/3.0 Pamidronate 
45 mg five 
times
Hydration, 
prednisolone
11 months
Table 1: Systematic review of previously published case reports using bisphosphonate treatment in patients with vitamin D intoxication. (Continued)Jensterle et al. Cases Journal 2010, 3:78
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mistakenly taking 75 drops (2.5 ml) of dihydrotachysterol
per day for the last 6 to 8 weeks instead of his usual daily
dose of 50 drops (1.7 ml). The reason for this sudden
change of his regimen remained a mystery. On the fourth
day after admission serum calcium dropped rapidly to the
reference range. The observed constipation and polyuria
resolved in few days after normalization of serum cal-
cium concentrations. The treatment for hypoparathy-
roidism had to be reinstituted 10 days after
dihydrotachysterol had been discontinued. The patient
was now easily switched to shorter acting vitamin D deri-
vate calcitriol (0.25 μg twice per day) which maintained a
normal serum and urinary calcium concentration with-
out a thiazide. However, two weeks after the discharge
from the department of endocrinology he discontinued
calcitriol and again started taking dihydrotachysterol,
since old habits die hard. Laboratory values and treat-
ment during follow up are reported in Figure 1.
Conclusion
Most symptoms of hypercalcemia are non-specific and
are difficult to be perceived by physicians. It should be
realized that vitamin D in all its forms can be a demand-
ing drug to use in a lifelong treatment of hypoparathy-
roidism. Continuous vigilance is required, especially in
older people. In comparison to short acting vitamin D
derivatives hypercalcemic episodes with dihydrotachys-
t e r ol  a ppear  t o  las t l ong e r a nd m a y  oc cur  wit h highe r
incidence. Whenever possible, a switch to shorter acting
vitamin D derivatives is recommended. The first line
treatment of vitamin D intoxication includes intravenous
hydration, diuretics and glucocorticoids. Since hypercal-
cemia of hypervitaminosis D is predominantly caused by
increased bone resorption, bisphosphonates might pro-
vide more effective treatment. We reported that the
instant use of pamidronate and methylprednisolone for
moderate to severe hypercalcemia due to vitamin D
intoxication with dihydrotachysterol is an effective treat-
ment choice. Considering the prompt response we
believe that bisphosphonates should be initiated in the
early stages of treatment of vitamin D intoxication.
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Figure 1 Laboratory findings and treatment follow up. Reference 
range for serum calcium is 2.1-2.6 mmol/L.
Table 2: Laboratory findings upon admission.
Patient Reference range
S-calcium 3.7 2.1-2.6 mmol/L
S-phosphate 1.1 0.8-1.4 mmol/L
S-creatinine 188 44-97 μmol/L
Urinary calcium excretion in the 24 hour 
collection
1.1 0.13-0.45 mmoL/mmoL of the creatinine
Alkaline phosphatase 1.08 < 1.5 μcat/L
Parathormone < 3 12-72 ng/L
25 OH D3 46 > 75 nmol/L
1,25 di OH vitamin D3 14 40-155 pmol/L
PSA 1.36 < 3 μg/L
ACE 0.17 0.13 - 0.47 μcat/LJensterle et al. Cases Journal 2010, 3:78
http://www.casesjournal.com/content/3/1/78
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